Qualia Clinical Services, a division of Holmes Biopharma, selects ALPHADAS, Logos Technologies electronic data capture (EDC) system to streamline and automate clinical trials in its Phase I clinical facility in Omaha, Nebraska.
Qualia Clinical Services chooses ALPHADAS for Phase I Clinical TrialsFor immediate release London, UK, October 21st 2008 Qualia Clinical Services, a highly regarded division of Holmes Biopharma, selects ALPHADAS®, Logos Technologies electronic data capture (EDC) system to streamline and automate clinical trials in its Phase I clinical facility in Omaha, Nebraska."Automating our recently expanded Phase I facility with ALPHADAS will enable us to provide our Pharma and Biotech sponsors with top quality, real time access to critical data while conducting state-of-the-art clinical trials," Azhar Kalim, COO of Qualia Clinical Services, Inc. “We are committed to helping our clients accelerate their time-to-market. We decided to re-evaluate the market because our previous EDC vendor was not meeting our business needs. We chose industry leading ALPHADAS to achieve our operational goals,” Dr. Sohail Khattak, CEO/President and CSO.Logos Technologies has been providing early phase EDC and clinical site automation tools to the pharmaceutical industry for over 12 years. "We are delighted to welcome Qualia Clinical Services as a new client and value this opportunity to facilitate its operational goals" said Giles Wilson, BEng, co-founder of Logos Technologies. "The partnership will help our mission to become the world’s leading early phase EDC and clinical trial automation company, assisting organizations to reduce the development time of life-saving and life-enhancing drugs.”The rapid success of Qualia's Phase I facility, which opened in the fall of 2006, necessitated the recent addition of 10,000 square feet. The clinic now boasts a total of 33,000 square feet, a bed capacity of over 160 beds and more than 150 professional staff. Additionally, administrative, operational and recreational areas were completely redesigned to better serve clients and study participants. Qualia Clinical Services, is changing lives for the better by providing its partners in the clinical research industry the full capabilities to complete early and late phase clinical trials. A full service contract research organization, Qualia has state-of-the-art clinical operations in Omaha, Nebraska , Toronto, Canada and Kiev, Ukraine. More information about Qualia can be obtained through its website at www.qualiaclinical.com Logos Technologies is a leading provider of world-class integrated clinical trial solutions to the world’s pharmaceutical, biotechnology and clinical research organisations. ALPHADAS is a clinical study management and fully mobile early Phase proactive EDC system that has been designed for real time eSource data collection. The system provides time based data entry at the bedside, collection and integration of laboratory data, images and scans and Bar-coded labeling to track samples from draw to dispatch. Logos Technologies established and proven product ALPHADAS sets the standard in collecting early Phase clinical trial data. ALPHADAS is fully compliant with industry standards and guidelines including FDA 21 CFR Part 11. More information about Logos Technologies can be obtained through its website at www.logostechnologies.com For more information contactLogos Technologies Ltd - Angela King Qualia Clinical Services – Azhar KalimAngela.king@logostechnologies.com Akalim@qualiaclinical.comwww.logostechnologies.com www.qualiaclinical.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.